Trade Cryoport, Inc. - CYRX CFD

Trading Conditions
Spread0.11
Long position overnight fee
Long position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
-0.026179 %
(-US$1.05)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


-0.026179%
Short position overnight fee
Short position overnight fee

Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
0.003957 %
(US$0.16)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00


0.003957%
Overnight fee time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20
Stock exchangeUnited States of America
Commission on trade10%

Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close16.11
Open15.61
1-Year Change-29.05%
Day's Range15.07 - 16.2

Cryoport Inc. Company profile

About CryoPort Inc

Cryoport, Inc. is a provider of integrated temperature-controlled supply-chain solutions to the biopharma/pharma, animal health, and reproductive medicine markets. The Company provides supply chain technologies and services through its brands, such as Cryoport Systems, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. The Company's products include Cryoport Express Shippers, Cryoport ELITE Shippers, Cryoport Cryosphere, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature Controlled Logistics, CRYOPDP Direct to Patient Solutions, CRYOPDP Control Tower Solution, MVE Biological Solutions Fusion Cryogenic Freezers and MVE Biological Solutions Vario Cryogenic Freezer. It operates primarily in Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). Its wholly owned subsidiaries include Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions, US LLC, and Cryoport Netherlands B.V.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CryoPort Inc revenues increased from $78.7M to $222.6M. Net loss applicable to common stockholders increased from $75M to $283.7M. Revenues reflect Americas segment increase from $49.6M to $120.3M, Europe & Middle East & Africa (EMEA) segment increase from $20.3M to $59.3M. Higher net loss reflects General and administrative - Balancing v increase of 74% to $85.1M (expense).

Equity composition

Common Stock $.001, 2/11, 250M auth., 26,723,426 issd. Insiders own approx. 0.09%. 02/10, 1-for-10 reverse split. 02/10, Exchange changed from NASDAQ to OTC.05/15, 1-for-12 Reverse stock split.